Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Short Interest Report for September

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 8,346,026 shares, an increase of 71.9% from the September 15th total of 4,853,831 shares. Based on an average daily volume of 2,551,015 shares, the days-to-cover ratio is currently 3.3 days. Approximately 5.9% of the company’s shares are short sold.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Truist Financial increased their target price on shares of Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Weiss Ratings downgraded Inventiva from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, October 8th. Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Cantor Fitzgerald assumed coverage on shares of Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $15.86.

Inventiva Trading Down 5.5%

Shares of NASDAQ:IVA traded down $0.17 during mid-day trading on Friday, reaching $2.94. The company had a trading volume of 4,854,208 shares, compared to its average volume of 958,441. The company’s 50-day moving average price is $4.08 and its 200-day moving average price is $4.48. Inventiva has a one year low of $2.82 and a one year high of $7.98.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.75 million during the quarter. Sell-side analysts expect that Inventiva will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IVA. Platt Investment Counsel LLC purchased a new stake in Inventiva during the third quarter valued at about $45,000. Engineers Gate Manager LP increased its stake in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Inventiva in the first quarter worth about $1,111,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Inventiva in the fourth quarter worth about $603,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.